Hepatotropic drugs: a study of the range and socio-economic availability in Ukraine for 2015-2017
Keywords:chronic liver diseases, hepatotropic drugs, socio-economic accessibility
Topicality. Liver diseases remain an important health problem in Ukraine and around the world. The increase of chronic liver diseases is called the “second epidemic of our century” after the “epidemic” of cardiovascular disease. Hepatotropic drugs (HTD) are the major in treatment of liver diseases.
Aim. To research the range and socio-economic availability of HTDs in Ukraine for 2015-2017.
Materials and methods. Analysis of the HTDs range was carried out according to the data retrieval system “Pharmstandard” of the company “Morion”. The socio-economic availability of drugs was investigated in terms of the adequacy of solvency (Cas.s.), showing the percentage of wages in % for a monthly course of treatment.
Results and dicussion. The range of HTDs in Ukrainian pharmaceutical market is quite wide and is presented during 2015-2017. 181-173 trade names (TH) based on 7 INN. The most accessible for the monthly course of treatment of patients with chronic liver diseases are herbal hepatoprotectors of silymarin – A05B A03 (72.2-72.7 %) and their combinations – A05B A53 (66.6 %). Other hepatotropic drugs were less accessible to the public, especially preparations of ursodeoxycholic acid and ornithine oxoglurate, which are generally classified as low accessible.
Conclusions. Despite the considerable range of HTDs in the pharmaceutical market of Ukraine, their availability indicators for 2015-2017 gradually declined for the population of Ukraine.
Babak, A. Ia. (2013). Sovremennaia gastroenterologiia, 2, 12–20.
Zviahyntseva, T. D., Chernobai, A. I. (2014). Suchasna hastroenterolohiia, 4, 70–76.
Abduieva, F. M., Bychkova, O. Yu., Bondarenko, I. O. (2011). Klinichna farmakolohiia: pidruchnyk dlia studentiv i likariv. Kharkiv: KhNU imeni V. N. Karazina, 405.
Kharchenko, N. V., Anokhina, G. A., Chekman, S. І. (2013). Novosti meditciny i farmatcii. Gastroenterologiia, 457, 5–6.
Ferenci, P., Scherzer, T., Kerschner, H., Rutter, K., Beinhardt, S., Hofer, H., … Steindl–Munda, P. (2008). Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy. Gastroenterology, 135 (5), 1561–1567. https://doi.org/10.1053/j.gastro.2008.07.072
Morozov S. V., Kucheryavyy Yu. A. (2012) Gepatoprotektory v klinicheskoy praktike: ratsionalnyye aspekty ispolzovaniya. Moscow: Forte Print. 7–29.
Binder, T., Salaj, P., Zima, T., & Vítek, L. (2006). Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine, 34 (5), 383–391. https://doi.org/10.1515/jpm.2006.077
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., … Spénard, J. (2011). A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. Journal of Hepatology, 54 (5), 1011–1019. https://doi.org/10.1016/j.jhep.2010.08.030
Prohramnyi kompleks «Apteka» kompanii «Morion». (n. d.). Available at: https://pharmbase.com.ua/ru/
Yakovlieva, L. V., Mishchenko, O. Ya., Adonkina, V. Yu. (2017). Farmakoepidemiolohichni doslidzhennia obsiahiv spozhyvannia antyhipertenzyvnykh likarskykh zasobiv v Ukraini : monohrafiia. Kharkiv: NFaU, 108.
Derzhavna sluzhba statystyky Ukrayiny. (n.d.). Available at: www.ukrstat.gov.ua
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).